PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Langslet, Gisle
TI  - Glycemic Improvement with Canagliflozin is Durable in T2DM Patients on Metformin
DP  - 2013 Dec 01
TA  - MD Conference Express
PG  - 24--25
VI  - 13
IP  - 17
4099  - http://mdc.sagepub.com/content/13/17/24.short
4100  - http://mdc.sagepub.com/content/13/17/24.full
AB  - The sodium glucose cotransporter 2 inhibitor canagliflozin is associated with durable glycemic improvement over 104 weeks compared with glimepiride in patients with type 2 diabetes mellitus (T2DM) on background metformin therapy. Such was the primary finding of a Phase 3 randomized, double-blind efficacy and safety study.